Hk Inno.n Corporation

Ewha University-Industry Collaboration Foundation

Cj Healthcare Corporation

Future Medicine Co., Ltd.

Hyuk Woo Lee

Eun Sun Kim

Kwang Do Choi

Dong Hyun Ko

Jae Hong Kweon

SeungPyeong Heo

Chae Young Ryu

Young Ju Kim

Soo Yeon Jung

Jae Wook Yang

Sung Ah Lee

Seung Chan Heo

Lak Shin Jeong

Seung Chan Kim

Ji-Yeon Park

So Young Ki

Mi Ra Yu

Ji Youn Lee

Jee Young Kim

Ji Yun Lee

Chong-Woo Park

Dongkyu Kim

Ha Na Yu

Ho-Youl Lee

Bo Mi Park

Myeongjoong Kim

Ye-Lim Lee

Mi Kyung Ji

Seungpyeong Heo

Seung Pyeong Heo

The present disclosure relates to a pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases including the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.

Pharmaceutical composition comprising adenosine derivative for prevention and treatment of retinal disease or optic nerve disease

A preparation method according to the present invention makes it possible to industrially produce large amounts of highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield by use of commercially available reagents and solvents. In addition, the use of novel intermediates according to the present invention makes it possible to produce highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield.

Intermediates for optically active piperidine derivatives and preparation methods thereof

The present invention provides a novel compound having a protein kinase inhibition activity, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to the present invention show a protein kinase inhibition activity, thus being effective in preventing or treating diseases related to protein kinase, such as cancer, autoimmune disease, neurological disease, metabolic disease, infection or the like.

Heterocyclic compound as a protein kinase inhibitor

The present invention relates to a novel crystalline form of a benzimidazole derivative and a preparation method thereof. The novel crystalline form according to the present invention is hardly changed chemically and/or physically under a long-term photo-stressed condition, has a low hygroscopicity, and has an extremely low static-electricity-inducing capability, thus being advantageous for formulation, and due to the excellent stability of the crystal form itself, it is very useful for long-term storage of the compound.

Crystalline form of a benzimidazole derivative and a preparation method thereof

The present invention relates to a method for preparation of MLN4924 as an E1 activating inhibitor, and more specifically, to a method for efficient and stereoselective preparation of MLN4924 by means of key steps involving stereoselective reduction of cyclopentenone with isopropylidene, regioselective cleavage of isopropylidene moiety, and synthesis of cyclic sulfate.

Preparation method of MLN4924 as an E1 activating inhibitor

Growing community of inventors

Gyeonggi-do, South Korea

Hyuk Woo Lee